Clinicopathological and prognostic characteristics of breast cancers (n = 247) dichotomized by cytokeratin 5/6 (CK5/6) status
| Variable . | CK5/6− . | CK5/6+ . | ORa [95% CI] . | P . | 10-yr survival . | No. of events . | P valueb (survival) . |
|---|---|---|---|---|---|---|---|
| Age of diagnosis (yr) | |||||||
| (25–50) | 51 | 49 | 1.00 | 64.9% | 31 | … | |
| [50–65] | 101 | 46 | 0.47 [0.28–0.80] | 0.005 | 75.3% | 30 | .048 |
| Tumor size (cm) | |||||||
| (0–2) | 88 | 40 | 1.00 | 83.8% | 17 | … | |
| [2–11] | 56 | 53 | 2.08 [1.23–3.54] | 0.008 | 58.6% | 40 | <.0001 |
| Nuclear grade | |||||||
| Grade 1 | 53 | 11 | 1.00 | 89.6% | 5 | … | |
| Grade 2 | 70 | 26 | 1.79 [0.81–3.94] | 0.18 | 72.4% | 22 | .007 |
| Grade 3 | 29 | 58 | 9.64 [4.38–21.2] | 0.0001 | 54.9% | 34 | <.0001 |
| Lymph node status | |||||||
| Negative | 75 | 49 | 1.00 | 82.0% | 19 | … | |
| Positive | 60 | 42 | 1.07 [0.63–1.83] | 0.89 | 57.5% | 38 | .0002 |
| ER IHC | |||||||
| Negative | 41 | 50 | 1.00 | 55.4% | 35 | … | |
| Positive | 111 | 45 | 0.33 [0.19–0.57] | <0.0001 | 79.9% | 26 | <.0001 |
| p53 IHC | |||||||
| Negative | 124 | 63 | 1.00 | 76.6% | 36 | … | |
| Positive | 27 | 32 | 2.33 [1.29–4.23] | 0.006 | 54.2% | 25 | .0002 |
| HER2 IHC | |||||||
| Faint staining | 139 | 80 | 1.00 | 74.3% | 48 | … | |
| Weak/strong | 13 | 15 | 2.01 [0.91–4.43] | 0.099 | 45.8% | 13 | .004 |
| BRCA1 germ-line mutation | |||||||
| Negative | 145 | 75 | 1.00 | 72.3% | 52 | … | |
| Positive | 7 | 20 | 5.52 [2.24–13.7] | 0.0001 | 61.6% | 9 | .20 |
| p27Kip1 IHC | |||||||
| Negative | 79 | 62 | 1.00 | 65.0% | 42 | … | |
| Positive | 62 | 27 | 0.56 [0.32–0.97] | 0.051 | 80.4% | 14 | .005 |
| Cyclin E IHC | |||||||
| Negative | 128 | 51 | 1.00 | 77.0% | 35 | … | |
| Positive | 22 | 41 | 4.68 [2.54–8.62] | 0.0001 | 51.4% | 26 | <.0001 |
| GMP IHC | |||||||
| None | 128 | 64 | 1.00 | 74.5% | 41 | … | |
| Few | 12 | 22 | 3.67 [1.71–7.88] | 0.0001 | 56.4% | 14 | .008 |
| Moderate/many | 1 | 6 | 12.0 [1.41–101.8] | 0.008 | 21.4% | 5 | <.0001 |
| Chemotherapy | |||||||
| No | 85 | 42 | 1.00 | 79.7% | 22 | … | |
| Yes | 64 | 51 | 1.61 [0.96–2.72] | 0.09 | 61.2% | 38 | .0023 |
| Hormonal therapy | |||||||
| No | 68 | 53 | 1.00 | 61.2% | 42 | … | |
| Yes | 76 | 34 | 0.57 [0.33–0.99] | 0.057 | 83.5% | 16 | .0008 |
| Variable . | CK5/6− . | CK5/6+ . | ORa [95% CI] . | P . | 10-yr survival . | No. of events . | P valueb (survival) . |
|---|---|---|---|---|---|---|---|
| Age of diagnosis (yr) | |||||||
| (25–50) | 51 | 49 | 1.00 | 64.9% | 31 | … | |
| [50–65] | 101 | 46 | 0.47 [0.28–0.80] | 0.005 | 75.3% | 30 | .048 |
| Tumor size (cm) | |||||||
| (0–2) | 88 | 40 | 1.00 | 83.8% | 17 | … | |
| [2–11] | 56 | 53 | 2.08 [1.23–3.54] | 0.008 | 58.6% | 40 | <.0001 |
| Nuclear grade | |||||||
| Grade 1 | 53 | 11 | 1.00 | 89.6% | 5 | … | |
| Grade 2 | 70 | 26 | 1.79 [0.81–3.94] | 0.18 | 72.4% | 22 | .007 |
| Grade 3 | 29 | 58 | 9.64 [4.38–21.2] | 0.0001 | 54.9% | 34 | <.0001 |
| Lymph node status | |||||||
| Negative | 75 | 49 | 1.00 | 82.0% | 19 | … | |
| Positive | 60 | 42 | 1.07 [0.63–1.83] | 0.89 | 57.5% | 38 | .0002 |
| ER IHC | |||||||
| Negative | 41 | 50 | 1.00 | 55.4% | 35 | … | |
| Positive | 111 | 45 | 0.33 [0.19–0.57] | <0.0001 | 79.9% | 26 | <.0001 |
| p53 IHC | |||||||
| Negative | 124 | 63 | 1.00 | 76.6% | 36 | … | |
| Positive | 27 | 32 | 2.33 [1.29–4.23] | 0.006 | 54.2% | 25 | .0002 |
| HER2 IHC | |||||||
| Faint staining | 139 | 80 | 1.00 | 74.3% | 48 | … | |
| Weak/strong | 13 | 15 | 2.01 [0.91–4.43] | 0.099 | 45.8% | 13 | .004 |
| BRCA1 germ-line mutation | |||||||
| Negative | 145 | 75 | 1.00 | 72.3% | 52 | … | |
| Positive | 7 | 20 | 5.52 [2.24–13.7] | 0.0001 | 61.6% | 9 | .20 |
| p27Kip1 IHC | |||||||
| Negative | 79 | 62 | 1.00 | 65.0% | 42 | … | |
| Positive | 62 | 27 | 0.56 [0.32–0.97] | 0.051 | 80.4% | 14 | .005 |
| Cyclin E IHC | |||||||
| Negative | 128 | 51 | 1.00 | 77.0% | 35 | … | |
| Positive | 22 | 41 | 4.68 [2.54–8.62] | 0.0001 | 51.4% | 26 | <.0001 |
| GMP IHC | |||||||
| None | 128 | 64 | 1.00 | 74.5% | 41 | … | |
| Few | 12 | 22 | 3.67 [1.71–7.88] | 0.0001 | 56.4% | 14 | .008 |
| Moderate/many | 1 | 6 | 12.0 [1.41–101.8] | 0.008 | 21.4% | 5 | <.0001 |
| Chemotherapy | |||||||
| No | 85 | 42 | 1.00 | 79.7% | 22 | … | |
| Yes | 64 | 51 | 1.61 [0.96–2.72] | 0.09 | 61.2% | 38 | .0023 |
| Hormonal therapy | |||||||
| No | 68 | 53 | 1.00 | 61.2% | 42 | … | |
| Yes | 76 | 34 | 0.57 [0.33–0.99] | 0.057 | 83.5% | 16 | .0008 |
OR, odds ratio; CI, confidence interval; ER, estrogen receptor; IHC, immunohistochemistry; GMP, glomeruloid microvascular proliferation.